In less than a year 23andMe has surpassed its annual goal in recruiting individuals for the Global Genetics Project, which will help diversify our research database and drive inclusion of understudied populations.
While we take a traditional approach to rigorous scientific inquiry and publishing our findings — we now have more than 110 papers that have appeared in peer-reviewed publications, some of which have taken months and often years to complete — we also occasionally take a lighter approach to sharing insights from customers who have consented to participate in research.
The U.S. Food and Drug Administration (FDA) granted 23andMe authorization to offer reports to customers on pharmacogenetics, indicating how customers’ genetics may influence the way they metabolize certain medications.
This week, thousands of people will flock to San Diego for one of the most important conferences of the year. No, not Comic-Con — it’s the annual meeting of the American Society of Human Genetics, the flagship conference for scientists who study the human genome.
To ensure that our customers can easily see how their contributions are making a difference, 23andMe has added a new Research Overview page, which will roll out to customers over the next few weeks. On the page, customers can see in one place the latest surveys, new studies and data on how customers are participating in research.
We’re reprinting this interview with Paul Cannon, Ph.D, about treatment for his Parkinson’s as well as updates on 23andMe’s research, that was put together by Tomorrow Edition blogger Benjamin Stecher.
Today, 23andMe is thrilled to announce that we are launching a collaboration with GlaxoSmithKline (GSK) to accelerate our ability to make those novel treatments and cures a reality.
A new Genetic Health Risk Report for G6PD Deficiency looks for one genetic variant linked to episodes of anemia.
Last month 23andMe received the first-ever FDA authorization for a direct-to-consumer genetic health risk test for cancer.
Earlier this month 23andMe added a new Carrier Status* report on a serious but rare condition that can lead to excessive insulin production.
